Ascentage Pharma to Showcase Advancements at J.P. Morgan Conference 2025 Ascentage Pharma's CEO will present at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting innovations in cancer therapies, January 2025.

Ascentage Pharma to Showcase Advancements at J.P. Morgan Conference 2025 #USA #San_Francisco #Ascentage_Pharma #cancer_therapies #J.P._Morgan_Conference

ASH 2024 Highlights Ascentage Pharma's Promising Clinical Data on Lisaftoclax for Relapsed/Refractory Multiple Myeloma Ascentage Pharma showcased encouraging outcomes from its Bcl-2 inhibitor, lisaftoclax, at ASH 2024, indicating significant potential for treating relapsed/refractory multiple myeloma patients.

ASH 2024 Highlights Ascentage Pharma's Promising Clinical Data on Lisaftoclax for Relapsed/Refractory Multiple Myeloma #USA #San_Diego #Ascentage_Pharma #Multiple_Myeloma #Lisaftoclax

ASH 2024: Ascentage Pharma Unveils Promising Findings for Lisaftoclax in Myelodysplastic Syndrome Treatment Ascentage Pharma recently shared new clinical data for its Bcl-2 inhibitor, Lisaftoclax, at ASH 2024, showcasing significant potential in treating myelodysplastic syndrome while ensuring safety for patients.

ASH 2024: Ascentage Pharma Unveils Promising Findings for Lisaftoclax in Myelodysplastic Syndrome Treatment #USA #San_Diego #Ascentage_Pharma #MDS #Lisaftoclax

ASH 2024 Highlights: Olverembatinib Shows Promise for CML Treatment At ASH 2024, Ascentage Pharma presented compelling data on olverembatinib, showcasing its effectiveness in treating chronic myeloid leukemia resistant to prior TKIs.

ASH 2024 Highlights: Olverembatinib Shows Promise for CML Treatment #United_States #San_Diego #Olverembatinib #CML #Ascentage_Pharma

Potential of Ascentage Pharma's Lisaftoclax in Treating CLL/SLL Showcased at ASH 2024 At ASH 2024, Ascentage Pharma unveiled promising clinical data for Lisaftoclax, a Bcl-2 inhibitor, showing effectiveness in CLL patients previously treated with Venetoclax.

Potential of Ascentage Pharma's Lisaftoclax in Treating CLL/SLL Showcased at ASH 2024 #USA #San_Diego #Ascentage_Pharma #Lisaftoclax #CLL_Treatment

ASH 2024 Reveals Promising Results for Olverembatinib and Lisaftoclax in Treating Pediatric Leukemia At ASH 2024, Ascentage Pharma presented data showing the combination of olverembatinib and lisaftoclax could be an effective chemotherapy-free treatment for R/R Ph+ ALL in children.

ASH 2024 Reveals Promising Results for Olverembatinib and Lisaftoclax in Treating Pediatric Leukemia #USA #San_Diego #Olverembatinib #Ascentage_Pharma #Lisaftoclax

New Indication for Olverembatinib Added to China's National Drug Reimbursement List for 2024 Ascentage Pharma announces that olverembatinib has been included in China's 2024 National Reimbursement Drug List for CML treatment. This expands access for patients.

New Indication for Olverembatinib Added to China's National Drug Reimbursement List for 2024 #China #Olverembatinib #CML #Suzhou #Ascentage_Pharma

Ascentage Pharma Welcomes New Directors to Strengthen Its Board Ascentage Pharma announces the appointment of Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors, enhancing its leadership team in biopharmaceuticals.

Ascentage Pharma Welcomes New Directors to Strengthen Its Board #USA #Ascentage_Pharma #Marina_Bozilenko #Debra_Yu #Rockville